ArticleCirculation reports2026
Short- and Mid-Term Outcomes of Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation in Octogenarians.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Robotic mitral valve repair (r-MVr) offers potential advantages, but its safety and feasibility in patients aged ≥80 years remain unclear. Methods and Results: This single-center retrospective cohort study included 53 consecutive patients aged ≥80 years who underwent MVr for degenerative mitral regurgitation between April 2011 and July 2025: 31 patients underwent r-MVr using the da Vinci Xi system, and 22 underwent conventional MVr (c-MVr). The primary outcomes were 30-day mortality, major complications, lengths of intensive care unit and hospital stay, and postoperative echocardiography findings. One 30-day death occurred after r-MVr (3.2%) due to intestinal ischemia, and none occurred after c-MVr. The postoperative hospital stay was shorter after r-MVr (12 [interquartile range (IQR), 8-13] vs. 13 [IQR, 12-15] days; P=0.04). The transmitral pressure gradient was lower in the r-MVr group than in the c-MVr group (2.1 [IQR, 2.0-3.0] vs. 3.0 [IQR, 2.0-3.9] mmHg; P=0.02). At the mid-term follow-up, there were no significant differences between the groups in 5-year overall survival (83.3% vs. 95.2%; P=0.32) or freedom from recurrent mitral regurgitation ≥ grade 3 (95.2% vs. 100%; P=0.49). Conclusions: r-MVr can be a safe and feasible minimally invasive option with acceptable short- and mid-term outcomes in octogenarians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.